profit from every $100 of sales.
$0$100
Vivos Therapeutics
$0.09+4.87% today
-96.5% in 1 year
1-year low $0.091-year high $2.59
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Vivos Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $16.0 million in 2022 to $17.4 million in 2025, with -$21.2 million of profit last year.
SalesProfit
Vivos Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Vivos Therapeutics | No profit yet | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads Vivos Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 16 | 14 | 15 | 17 | |
| 10 | 8 | 9 | 11 | |
| -25 | -17 | -11 | -20 | |
| -24 | -17 | -11 | -19 | |
| -24 | -14 | -11 | -21 | |
| -25.90 | -11.14 | -2.22 | -2.07 | |
| 62.5% | 59.9% | 60.0% | 60.4% | |
| -156.2% | -125.3% | -74.3% | -114.1% | |
| -148.8% | -98.4% | -74.1% | -121.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 14 | 11 | 15 | 25 |
| Cash | 4 | 2 | 6 | 2 |
| Total debt | 2 | 2 | 2 | 14 |
| Total liabilities | 9 | 10 | 7 | 27 |
| 5 | 0 | 8 | -1 | |
| 1 | 1 | 5 | 10 | |
| -274.1% | -567.9% | -93.2% | -130.8% | |
| -496.7% | -3,304.9% | -140.0% | 1,424.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -20 | -12 | -13 | -15 | |
| 1 | 1 | 1 | 2 | |
| -21 | -13 | -13 | -18 | |
| Dividends paid | – | – | – | – |
| 0 | – | – | – | |
| 2 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- -4.0×
- 0.2×
- –
- –
- -578.8%
- -698.0%
- 0.0%
Profitability
- 60.4%
- -114.1%
- -121.7%
- -106.6%
- -123.2%
- -252.8%
- -846.5%
- -84.4%
- -281.2%
- –
Growth
- +2.9%
- –
- −32.8%
- –
- +86.5%
Financial health
- –
- -9.06
- 53.7%
- –
- 0.24
- 0.24
- 0.69
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 888
Bottom 24%of 889
What analysts expect
- Average price target
- $2.13
- Range
- $1.75 – $2.50
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 15, 2026 | -0.58 | -0.50 | −17.2% |
| Nov 19, 2025 | -0.49 | -0.53 | +7.5% |
| Aug 19, 2025 | -0.55 | -0.27 | −103.7% |
| May 15, 2025 | -0.45 | -0.44 | −2.3% |
| Mar 31, 2025 | -0.28 | -0.43 | +34.9% |
| Nov 14, 2024 | -0.40 | -0.70 | +42.9% |
| Aug 14, 2024 | -0.60 | -1.05 | +42.9% |
| May 14, 2024 | -1.63 | -1.17 | −39.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
0No pass
Philip Fisher
31No pass
Peter Lynch
7No pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
22No pass
Questions about Vivos Therapeutics
Is Vivos Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Vivos Therapeutics AI analysis
What does Vivos Therapeutics do?
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It is in Medical - Devices.
Does Vivos Therapeutics pay a dividend?
No. Vivos Therapeutics does not pay a dividend at the moment.
Is Vivos Therapeutics stock halal?
No. Vivos Therapeutics does not pass our halal screen: its debt is 444% of its market value, at or above the 33% limit. How we check
How has Vivos Therapeutics stock done over the past year?
Down 96.5% over the past twelve months, to $0.09. It traded between $0.09 and $2.59 and is 96.5% below its high.
Who are Vivos Therapeutics's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Vivos Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.